To capture the onset (incidence, severity, intervention, outcome, and others) of febrile neutropenia in patients with extensive stage small cell lung cancer who receive durvalumab in combination with platinum agent and etoposide under the actual use.
To capture safety(FN) when IMF is administered to patients with extensive stage small cell lung cancer in clinical practice after launch